All posts by: Michael Zand

FDA Orphan Drug Designation Granted to Hemophilia Gene Therapy; Clinical Studies to Begin Soon – Rare Disease Report (blog)

FDA Orphan Drug Designation Granted to Hemophilia Gene Therapy; Clinical Studies to Begin SoonRare Disease Report (blog)The U.S. Food and Drug Administration (FDA) has granted Shire with orphan drug designation for its gene therapy candidate SHP654, in… Continue reading

Vanderbilt-Ingram Cancer Center Patients Treated with New FDA-Approved CAR T Therapy – Newswise (press release)

Winchester Herald ChronicleVanderbilt-Ingram Cancer Center Patients Treated with New FDA-Approved CAR T TherapyNewswise (press release)Newswise — Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in… Continue reading

Incyte to Develop MacroGenics’ Cancer Immunotherapy MGA012 in Up-to-$900M+ Collab – Genetic Engineering & Biotechnology News

Incyte to Develop MacroGenics’ Cancer Immunotherapy MGA012 in Up-to-$900M+ Collab Genetic Engineering & Biotechnology News Incyte will partner with MacroGenics to develop its Phase I cancer immunotherapy candidate MGA012, a monoclonal antibody designed to inhibit programmed cell death protein 1 (PD-1), through a collaboration that could generate up to $900 million-plus for … and more »